Johnson & Johnson announced that it will invest $55 billion in the United States over the next four years in manufacturing, research, and technology. This is a 25% increase compared to the previous four years.
“Today’s announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges,” Johnson & Johnson CEO Joaquin Duato said in a statement. “Our increased U.S. investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add U.S.-based jobs but manufacture cutting edge medicines to treat patients in America and around the world.”
The new “500,000 square foot, state-of-the-art biologics manufacturing facility” in North Carolina will “manufacture next-generation medicines for people living with cancer, immune-mediated and neurological diseases in America and around the world,” the company said in a press release.
The company will expand several existing locations and will develop “three new advanced manufacturing facilities,” the release said.
Some of its investments will include developing “lifesaving and life-changing treatments in areas such as oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery,” while its technology investment will “help make drug discovery and development faster, support workforce training and enhance our business operations.”
The White House said the investment is the “latest massive victory in President Donald J. Trump’s unrelenting pursuit of American manufacturing dominance.”
“President Trump will stop at nothing to restore American manufacturing and bring jobs back where they belong — right here in the U.S,” the statement read.
Other pharmaceutical companies, such as Eli Lilly, have also announced plans to invest billions in manufacturing plants across the United States.
The plants will be constructed over the next five years and will create more than 3,000 jobs for scientists and 10,000 jobs for construction workers. Three of the sites will be used for manufacturing active pharmaceutical ingredients (API) and “reshoring critical capabilities of small molecule chemical synthesis,” the company said in a press release. The fourth location will “extend the company’s global parenteral manufacturing network for future injectable therapies.”
